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Abstract: Proton pump inhibitors (PPIs) are the first-choice drugs used to prevent and treat acid-
related diseases. However, a lack of satisfactory response to the standard PPI dose (“PPI failure”) is
often reported, especially in patients with gastroesophageal reflux disease. Poor compliance seems to
be one of the main causes of PPI failure; hence, it is crucial to gain knowledge on how to properly
administer PPIs. In this review, we aimed to evaluate the effect of food, beverages, and dosing
regimen on pharmacokinetics and pharmacodynamics of PPIs and to frame recommendations for
healthcare professionals to improve both patient’s counseling and compliance to treatment with
PPIs. A total of 201 papers were identified following a literature search. After full-text evaluation, 64
studies were included in the review. Co-administration of PPIs with a meal may affect both their
bioavailability and effectiveness; however, the influence of food depends on the type of drug and its
formulation. Except for pantoprazole, PPIs can be administered in the morning or evening; however,
morning intake generally provides better daytime control of gastric acidity. In most cases, the choice
of the proper schedule of administration should be based on the patient’s symptoms and individual
dosing preferences.
Keywords: proton pump inhibitors; food; meal; interactions; alcohol; juice; dosing regimen; timing;
compliance; GERD
1. Introduction
Proton pump inhibitors (PPIs) are the first-choice drugs prescribed (1) for the treatment
of esophagitis, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD);
(2) as a part of eradication therapy for Helicobacter pylori; and (3) for the prevention of
nonsteroidal anti-inflammatory drugs (NSAIDs)-associated ulcers. The use of PPIs without
a prescription is widespread: in 2020, PPI tablets were among the five leading over-the-
counter (OTC) product categories in the USA, based on sales [1].
Despite the established position of PPIs in the treatment of acid-related diseases, a
lack of satisfactory response to the standard PPI dose (so-called “PPI failure”) is often
reported, especially in patients with GERD [2]. It is estimated that among patients with
GERD treated with PPI once daily, 10 to almost 40% of patients may still experience disease
symptoms [2,3]. Failure to respond to a PPI may not only affect the patient’s quality of life
but also result in increased healthcare costs (due to outpatient visits, diagnostic procedures,
etc.) [4].
In a non-erosive subtype of reflux disease (NERD) PPIs can be ineffective, because
symptoms are due to visceral hypersensitivity (and not the irritation by gastric acid) [5]. Poor
compliance seems to be another important cause for PPI failure—it is reported that 20–50%
of patients with GERD may use PPIs irregularly or administer them incorrectly [2,3,6]. For
PPIs, the appropriate dosing regimen and administration with food are crucial for the
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optimal treatment efficacy. The PPIs are prodrugs and require activation in the secretory
canaliculus of parietal cells. Because of this, the ingestion 30–60 min before a mealtime,
to ensure appropriate drug concentrations ahead of proton pump activation, is needed.
Consequently, the duration of therapeutic effect is partly dictated by the time of meals
but also drug formulation. In a recent randomized study of 64 patients with persistent
heartburn (despite treatment with 20 mg omeprazole), Waghray et al. [7] assessed whether
the correction of only the dosing regimen could improve the therapeutic effectiveness. After
6 weeks of adhering to the recommended omeprazole dosing regimen, both frequency
and severity scores in the GERD symptom assessment scale were significantly lower, and
considerable cost savings were reported [7].
Not only patients’ but also healthcare professionals’ knowledge of mealtime-related
dosing schedules of PPIs seems to be insufficient. Solem et al. [8] surveyed 501 patients
and 262 physicians and revealed that although 81% of patients took their PPIs as directed,
only 43% received recommendations from healthcare professionals that were compliant
with the product labeling. Moreover, an alarming finding was that only 55% of patients
were instructed by pharmacists on how to administer PPIs.
Our present review is aimed at evaluating the effect of food, beverages, and dosing
regimen on pharmacokinetics, pharmacodynamics and clinical effectiveness of PPIs and
framing recommendations for healthcare professionals to improve both patient’s counseling
and compliance to treatment with PPIs.
2. Materials and Methods
To collect data on this topic, the authors, namely AW and PP, performed a literature
search in Medline (via PubMed) and Embase databases, covering reports from 1985 to
2020. We used the following phrases and keywords during the search process: drug
names (“dexlansoprazole,” “esomeprazole,” “lansoprazole,” “omeprazole,” “pantopra-
zole,” “rabeprazole”) in combination with “food,” “food-drug interaction,” “meal,” “break-
fast,” “juice,” “alcohol,” “dosing regimen,” “timing,” “morning,” and “evening.” We also
researched other resources such as Micromedex, AHFS, drugs.com, and UpToDate as well
as monographs and prescribing information of particular medicinal products. Additional
publications were found by checking the reference lists.
All articles reporting or investigating the effect of meals, beverages, and dosing
regimen on pharmacokinetics, pharmacodynamics, and clinical effectiveness of PPIs were
considered for inclusion in this review. No restrictions were applied for study design,
sample size, or participants’ characteristics. We initially identified a total of 201 articles.
After excluding 20 duplicates and screening titles and abstracts of 181 papers, we rejected
77 articles due to not meeting inclusion criteria. Of 104 remaining articles, we excluded
29 reviews, 4 in vitro studies, 4 preclinical studies, and 3 articles written in languages other
than English. Finally, 64 original clinical studies were included in this review. Figure 1
presents a flowchart of the search strategy.
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3. Results and Discussion
.1. Aspects of PPI Pharmacokinetics
To act as H+,K+-ATPase enzyme inhibitors, PPIs need to be activated in an acidic envi-
ronment. Proton pump (H+,K+-ATPase) is the ultimate mediator of gastric acid secretion
by parietal cells and it was proposed that activation of H+ secretion occurred by incorpora-
tion of H+,K+-ATPase-rich tubulovesicles into the apical plasma membrane and that the
pumps were re-sequestered back into the cytoplasmic compartment on return to the resting
state [9]. PPIs (omeprazole, lansoprazole, rabeprazole, pantoprazole, esomeprazole) are
inactive prodrugs which are activated in the acid environment of the gastric glands. PPIs
act by inhibiting this pomp, which is located on the luminal surface of gastric parietal cells.
The inactive PPIs diffuse from the bloodstream into the parietal cells and subsequently into
the acid environment of the secretory canaliculi, where they rearrange to form a sulfenic
acid in equilibrium with a sulfenamide. Either chemical entity is then able to interact
covalently with thiol groups at cysteine residues located on the luminal surface of the
α-subunit of the H+,K+-ATPase. This covalent binding results in specific and essentially
irreversible inactivation of the enzyme, leading to inhibition of gastric acid secretion [9,10].
However, because of acid-lability, they are prone to degradation by luminal gastric
acid. Hence, PPIs are produced mainly in enteric-coated (EN) and delayed-release (DR)
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formulations that safely transport drugs to the place of their absorption: the proximal small
bowel [11]. Drug combinations with sodium bicarbonate are also marketed to temporarily
neutralize gastric pH.
Although the oral bioavailability of each PPI is different, in general, their pharmaco-
logical properties are similar [11]. All PPIs have extremely short t1⁄2 (approximately 1–2
h); however, the development of DR formulations solved this problem [12]. The overall
binding of PPIs to plasma proteins is 95% or greater [12].
All PPIs are metabolized by intestinal and hepatic P450 cytochromes: mainly CYP2C19
and CYP3A4; hence, their interactions may theoretically occur with other CYP substrates as
well as with the inhibitors and inducers of CYP isoenzymes. Nevertheless, the majority of
the interactions between PPIs and drugs metabolized by CYP isoenzymes are of no clinical
relevance. PPIs are known to inhibit activation of clopidogrel (prodrug metabolized by
CYP2C19) and may potentially reduce its antiplatelet activity. Still, even in this case, the
scientific evidence for the clinical impact of interaction is conflicting [13,14]. Pantoprazole,
lansoprazole, and dexlansoprazole seem to be the least susceptible to such interactions [11].
The reason for PPI failure may be also associated with the metabolism of these drugs.
The genetically determined defect in the CYP2C19 pathway was found common in certain
races and interethnic variation in the capacity to metabolize PPIs should be considered
during PPI pharmacotherapy. This defect may result in impaired metabolism of these
drugs giving rise to three distinct phenotypes: rapid, extensive and poor metabolizers [15].
Chang et al. [16] found that AUC of omeprazole differed significantly between the three
groups with a relative ratio of 1:3.7:20 between rapid, extensive and slow metabolizers.
It could have a significant effect on the treatment of acid-related diseases and results
in a lack of symptom relief and ineffective H. pylori eradication for rapid metabolizers
and on the other hand over-treatment, with increased frequency of adverse effects and
needless financial burden for poor metabolizers [15]. The wide interethnic variations
in CYP2C19 polymorphisms were observed. Dickson and Stuart [15] reported marked
interethnic variation in genotype and phenotype frequency, particularly with respect to
poor metabolizers (the variation in the frequency of poor metabolizers ranged from 2.1%
in Caucasians to 14.6% in Japanese) resulting in marked racial differences in the capacity
to metabolize PPIs. Interethnic differences should be recognized and established by the
specialist not only according to the effect and safety of therapy but also to improve cost–
benefit ratio.
The presence of food generally delays the absorption of PPIs and may decrease their
bioavailability [11]. However, the scope and clinical importance of this interaction strongly
depend on both the type of drug and formulation; hence, we discuss the effect of food for
each of the PPI representants separately.
3.2. Esomeprazole
Esomeprazole (syn. esomeprazole magnesium, esomeprazole strontium) is available
in DR formulations: capsules, granules for oral suspension, and tablets consisting of
pellets. The oral bioavailability of esomeprazole is 64% after a single 40 mg dose and 89%
after repeated administration [17]. In the fasted conditions, DR tablets and capsules of
esomeprazole are bioequivalent [18].
3.2.1. Food Effect
Several studies have revealed that food may significantly affect the pharmacokinetic
parameters of both esomeprazole magnesium and strontium formulations. Compared to
fasting conditions, intake of 40 mg esomeprazole dose with food decreased AUC by 43–53%
and Cmax by 74–78%, as shown by various studies [17–20]. Additionally, Liu et al. [21]
reported that concomitant ingestion of a 40 mg esomeprazole magnesium DR capsule
with a meal may significantly delay drug absorption (by 2.5–3 h). The high-fat meal had
800–1000 kcal (on average 150 kcal of protein, 250 kcal of carbohydrates, and 500–600 kcal
of fat).
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Sostek et al. [22] performed a randomized, open-label study to compare esomeprazole
pharmacokinetics when administered repeatedly under fed or fasted conditions. Forty-four
healthy subjects ingested 40 mg esomeprazole capsules for 5 days, on days 1 and 5: either
(1) 15 min before a high-fat meal or (2) 4 h before a standard meal, and on remaining days:
30 min before a standardized medium-fat breakfast. A high-fat meal consisted of toast
with butter, hash-brown potatoes, eggs, bacon, and whole milk. On day 1, changes in
esomeprazole bioavailability under fed vs. fasted conditions showed a similar pattern to
that previously reported: both AUC and Cmax decreased by 40% and 75%, respectively.
However, on day 5, the effect of meal timing on both parameters was considerably lower:
AUC decreased by 25% and Cmax by 23%. Although the meal consumption shortly before
esomeprazole intake significantly decreased drug bioavailability, Sostek et al. suggested
that it might be clinically irrelevant during the chronic therapy. Interestingly, another study
revealed that ingesting 40 mg esomeprazole dose 1 h before a high-fat meal may even
increase AUC and Cmax (by 25% and 50%, respectively) relative to the fasted conditions [20].
In two randomized, double-blind, placebo-controlled trials of 69 healthy volunteers,
Furuta et al. [23,24] assessed the influence of food on esomeprazole effectiveness measured
by changes in median intragastric pH and percentage time at pH > 4 (over a 24-h period and
during daytime). In the first study [23], the participants were administered a single 20 mg
esomeprazole capsule either 15 min before or 30 min after the supper. The supper contained
112.8 g of carbohydrates, 16.3 g of proteins, and 27.3 g of fat and had on average 762 kcal.
Median intragastric pH increased slightly when esomeprazole was taken before the supper
as compared to administration after a meal; however, the difference was nonsignificant. In
the second study [24], the same dose and formulation of esomeprazole was ingested either
(1) 30 min before or (2) 30 min after breakfast. In contrast to previous results, significant
differences were found between these two regimens. When esomeprazole was taken under
fed conditions, percentage time at pH > 4 was lower (over a 24-h period: 45.3% vs. 54.4%
in regimen (1), during daytime: 51.4% vs. 66.5%, respectively) as well as the median
intragastric pH (3.5 vs. 4.2). Furuta et al. concluded that intake of esomeprazole with food
may negatively influence its inhibitory effect on gastric acid secretion. These results are in
contrast to the information given in esomeprazole product monograph, where the effect of
food on the acid-inhibiting activity of the drug was considered as nonsignificant [25].
In a randomized, open-label trial of 32 patients with GERD treated with 40 mg
esomeprazole daily, Boltin et al. [26] evaluated whether the change in a dosing regimen
with regard to food would affect treatment effectiveness. After 2 weeks of ingesting
esomeprazole 30 min before breakfast, 16 of the participants were asked to switch to the
administration with a standard meal for the following 4 weeks. A standard meal consisted
of two slices of toast; either one egg, one piece of fruit, or 170 g yogurt; and 250 mL of tea,
coffee, or juice. At the beginning of the study and after each week, patients completed
standardized questionnaires: GERD frequency and severity index and the GERD-health-
related quality of life (GERD-HRQL). Both groups of patients administering esomeprazole
before breakfast and after a meal reported a decrease in the frequency and severity of
GERD symptoms as well as improvement in the quality of life. No significant changes were
observed between the study groups; hence, Boltin et al. [26] concluded that esomeprazole
effectiveness is maintained after administration with a meal.
3.2.2. Dosing Regimen
Wilder et al. [27] performed a randomized, cross-over study in 33 healthy volunteers to
assess the effect of different esomeprazole dosing regimens on 24 h, daytime, and nighttime
intragastric pH. For 5 days, the participants were given 20 mg or 40 mg esomeprazole
either (1) twice daily, or once daily (2) in the morning—before breakfast, (3) in the evening—
before dinner or at bedtime. Both 20 mg and 40 mg doses taken twice daily inhibited acid
suppression stronger than all once-daily regimens. The 24-h intragastric pH was higher for
regimen (2) than for regimen (3) (20 mg dose—4.3 vs. 3.8, 40 mg dose—4.8 vs. 4.4, respec-
tively) as well as daytime intragastric pH (20 mg dose—4.6 vs. 3.7, 40 mg dose—4.9 vs. 4.1,
Int. J. Environ. Res. Public Health 2021, 18, 3527 6 of 21
respectively). Contrastingly, nighttime acid inhibition improved when esomeprazole was
administered in the evening relative to the morning intake (20 mg dose—3.8 vs. 3.4, 40 mg
dose—4.8 vs. 4.3, respectively). On the basis of these results, Wilder et al. suggested that
the dosing regimen of esomeprazole should be chosen individually for each patient accord-
ing to the symptom pattern. Maejima et al. [28] also compared the effectiveness of different
esomeprazole doses and regimens of administration and concluded that esomeprazole
intake twice a day may provide higher gastric acid inhibition than intake once a day in
the morning.
3.2.3. Administration Modes
DR esomeprazole tablets and capsules can be swallowed whole. Additionally, all the
available esomeprazole formulations are allowed to be prepared and administered in a
liquid form. According to the prescribing information, tablets need to be dispersed only in
water [29], whereas for capsule content and granules, several other vehicles can be used [17].
Bladh et al. [30] found that the stability and dispersion features of esomeprazole granules
are maintained when suspended in apple juice, orange juice, or applesauce. Additionally,
in a randomized, open-label study of 41 healthy subjects, Andersson et al. [31] examined
whether the ingestion of 40 mg esomeprazole magnesium capsule content with applesauce
is bioequivalent to the whole capsule intake. Both administration modes resulted in
comparable AUC, Cmax, tmax, and t1⁄2 values. Similar results were obtained for co-intake of
esomeprazole strontium capsules with applesauce [19].
3.3. Omeprazole
Omeprazole (syn. omeprazole magnesium) is available in immediate-release (IR)
formulations: capsules and powder for oral suspension, and in DR formulations: tablets,
orally disintegrating tablets (ODTs), capsules, and granules to prepare an oral suspension.
The oral bioavailability of both IR and DR forms vary from 30 to 40% [32,33].
3.3.1. Food Effect
According to prescribing information, the presence of food may significantly affect
the bioavailability of IR omeprazole formulations. When capsules or powder for oral
suspension were administered 1 h after a meal, both AUC and Cmax decreased by 24% and
63%, respectively [32]. Liu et al. [34] performed a randomized, open-label study involving
30 healthy subjects who were given a single 40 mg IR omeprazole capsule (containing
sodium bicarbonate) while fasting or with a standard meal. The meal consisted of two
pieces of bread, two sausages, two eggs, 100 g of salad, and 250 mL of milk. Under fed
conditions, a significant decrease in AUC0-t and Cmax (by 28% and 47%, respectively) and
a delay of tmax (by 0.6 h) were observed relative to the fasting state. In a recent study,
Ochoa et al. [35] obtained similar results; hence, both research groups suggested that IR
omeprazole formulations should be administered under fasted conditions to improve the
effectiveness of therapy.
The reported effect of food on the pharmacokinetics of DR omeprazole capsules
is ambiguous. In a study of 17 healthy volunteers, Pillai et al. [36] revealed that after
concomitant intake of light breakfast and two different brands of DR 40 mg omeprazole
capsules, Cmax decreased significantly (by 24% and 40%, respectively) and tmax was delayed
(from 3 to 5 h for both products) However, no clinically relevant changes were detected
in AUC0–24 and AUC0–∞; hence, Pillai et al. concluded that food may delay the rate
(measured by Cmax) but not the extend (measured by AUC) of omeprazole absorption.
Similar statements were also made in several other studies [37,38]. Contrastingly, in a
randomized, open-label trial, Vaz-da-Silva et al. [39] suggested that a meal may affect both
the rate and extend of omeprazole absorption. Twenty-three healthy participants were
administered 20 mg DR omeprazole capsules of two different brands either under fasting
conditions or concomitantly with a high-fat breakfast. The breakfast had approximately
750 kcal (of which fat constituted on average 50%) and consisted of one slice of toast with
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butter, one unit of cereal with whole milk, two grilled strips of bacon, two scrambled
eggs, one croissant, and a noncitrus juice. After 7 days of each dosing regimen, significant
changes were observed in the pharmacokinetic profiles of both DR products: not only Cmax
decreased (by 58% and 63%), but AUC0–12 also decreased (by 35% and 38%). Additionally,
Liu et al. [34] reported a negative effect of food on the AUC of DR omeprazole capsules.
The bioavailability of DR omeprazole ODTs is also affected by food. A significant
decrease in AUC0–∞ and Cmax (by 19% and 56%, respectively) was observed, while tmax
was delayed by 2 h [40].
DR tablets appear to be the most food-resistant omeprazole formulation. In a ran-
domized, open-label study of 58 volunteers, Thomson et al. [41] assessed the influence of
food on DR omeprazole tablets repeatedly administered at the dose of 20 mg in different
regimens: (1) while fasting, (2) immediately before, or (3) after a standardized breakfast.
Except for the delay of tmax (2.2 h for (1) vs. 3.5 h for (3)), no significant changes were
observed in AUC and Cmax values between all the investigated regimens. Shinkai et al. [42]
reported the nonsignificant effect of food on 20 mg omeprazole pharmacokinetic param-
eters (namely Cmax, AUC0-t, tmax, and t1⁄2); however, in this study, drug formulation was
not mentioned.
Hatlebakk et al. [43] evaluated whether omeprazole should be taken shortly before
a meal or without it. In a study of 21 healthy subjects, a 20 mg capsule of omeprazole
was administered in the morning (1) 15 min before breakfast or (2) 4 h before lunch. The
breakfast contained a caloric load typical for each participant and included a piece of
bread or a muffin, milk or yogurt, and coffee or tea. After 8-h intragastric pH recording,
a difference in the median percentage time of pH < 4 was detected for omeprazole taken
before and without food (20.1% vs. 31.4%, respectively). The obtained results indicated that
omeprazole needs to be taken before a meal to maintain the optimal values of gastric acidity.
3.3.2. Omeprazole and Grapefruit Juice (GFJ) Consumption
Omeprazole is metabolized to 5-hydroxyomeprazole (by hydroxylation) and omepra-
zole sulphone (by sulfoxidation). The enzymes involved in these metabolic reactions
are CYP2C19 and CYP3A4, respectively. We found one randomized study [44] that in-
vestigated the effect of GFJ on omeprazole metabolism in 13 healthy subjects. After an
overnight fast, the participants were given a single 20 mg omeprazole dose either with
300 mL of GFJ or with water. Relative to the intake with water, GFJ consumption caused
a significant decrease in AUC0–12 and Cmax of omeprazole sulphone (by 20% and 19%,
respectively). Consequently, the index of CYP3A4 activity (AUC ratio of omeprazole sul-
phone to omeprazole) also decreased by 33%. No significant differences were detected in
the AUC of omeprazole and 5-hydroxyomeprazole as well as in the tmax and t1⁄2 of both
omeprazole and its two metabolites. It was concluded that CYP3A4, but not CYP2C19,
activity is inhibited by concomitant intake of omeprazole with GFJ. However, a year later,
Mouly et al. [45] pointed out several limitations of the abovementioned study, indicating
that even if the authors were correct, the clinical significance of GFJ-omeprazole interaction
remains unclear.
3.3.3. Interaction with Cranberry Juice
In vitro studies revealed that cranberry juice constituents may act as antiadhesive
agents on H. pylori. In a randomized double-blind study, Shmuely et al. [46] confirmed
that in female patients, the addition of 250 mL of cranberry juice to triple therapy with
omeprazole, amoxicillin, and clarithromycin can increase the rate of H. pylori eradication to
even 95.2%. However, Saltzman et al. [47] emphasized that ingesting cranberry juice to-
gether with omeprazole may significantly reduce gastric pH for 1 h after co-administration,
and consequently, omeprazole efficacy might be altered. Hence, regular but not occasional
consumption of cranberry juice should be avoided by patients chronically treated with
omeprazole and probably other PPIs as well. The effect of cranberry extract supplements
on gastric acidity remains unknown.
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3.3.4. Omeprazole and Alcohol Consumption
Brown et al. [48] assessed whether treatment with omeprazole may influence the
pharmacokinetics of ethanol. Twenty-three healthy participants consumed 4.8% beer
(containing ethanol in a dose of 0.6 g/kg b.w.) with a standardized meal either (1) alone—
control group or (2) after at least 2 weeks of omeprazole administration. The standardized
meal consisted of pasta—tagliatelle with ham and mushrooms (382 kcal, 37.9 g of carbo-
hydrate, 19.2 g of protein, 17 g of fat) and a dessert—yogurt with strawberry compote
(193 kcal, 26.3 g of carbohydrate, 6.5 g of protein, and 6.8 g of fat). In both the control and
omeprazole-treated groups, the consumption of beer with food resulted in a percentage
first pass ethanol metabolism of an average of 58%. No significant changes were observed
in ethanol AUC and Cmax between the two regimens. Similar results were obtained in
other smaller studies, which suggests that interaction between omeprazole and ethanol is
unlikely [49,50].
3.3.5. Dosing Regimen
Chiverton et al. [51] performed a randomized, double-blind, placebo-controlled study
to evaluate the effect of dosing regimen on omeprazole effectiveness. Six patients with duo-
denal ulcers were administered 20 mg omeprazole either in the morning or in the evening.
After 7 days of treatment, the mean 24-h intragastric pH in the morning, evening, and con-
trol groups were as follows: 3.9 ± 1.8, 2.9 ± 1.1, and 1.7 ± 0.1, respectively. Although both
omeprazole dosing schedules significantly decreased gastric acidity, omeprazole intake
in the morning was found to be the most effective. In another study, Prichard et al. [52]
made analogous observations in eight healthy subjects; however, the authors emphasized
that during nighttime, both morning and evening omeprazole administration provided
comparable control of gastric pH.
Hendel et al. [53] obtained interesting results in a study of 17 patients with GERD who
were administered 40 mg omeprazole once daily (1) in the morning or (2) in the evening.
After 14 days of each dosing schedule, a 24-h intragastric pH measurement was performed.
After morning omeprazole administration, daytime intragastric pH was 0.72 higher than
that observed after evening dosing. Contrastingly, after evening omeprazole intake, night-
time intragastric pH was 0.64 higher than that noted after morning intake. Moreover,
patients’ outcomes and preferences differed depending on the symptomatology of GERD.
Those with reflux induced by physical activity benefited from the morning regimen and
preferred it; those with mainly nocturnal symptoms, had their reflux abolished either after
only evening dose or after both morning and evening dose, however, favored evening
regimen. Hendel et al. concluded that the timing of omeprazole administration may have
a significant effect on both the 24-h intragastric pH profile and therapeutic effects; hence,
GERD symptomatology and patient’s preferences should be considered while choosing the
most appropriate dosing regimen.
It was observed that most patients who chronically administer PPIs still experience
nocturnal acid breakthrough (NAB)—nighttime periods with intragastric pH < 4 lasting
for 1 h or more. In order to prevent NAB, Hatlebakk et al. [54] evaluated which dosing
regimen of omeprazole would most efficiently suppress the nocturnal gastric acidity.
Eighteen healthy subjects were administered 40 mg omeprazole for 7 days in three dosing
regimens: (1) 40 mg once daily—before breakfast, (2) 40 mg once daily—before dinner,
or (3) 20 mg twice daily—before breakfast and dinner. The percentage time of nighttime
intragastric pH < 4 for each dosing regimen was as follows: (1) 66.3%, (2) 31.3%, and
(3) 20.5%, respectively; this indicated that both administration after dinner and splitting
omeprazole dosing are more effective than morning omeprazole intake in controlling
nighttime gastric acidity and consequently in preventing NAB. Additionally, Howden
et al. [55] indicated that the antisecretory effect of IR formulation was faster than that
observed with DR-omeprazole and a bedtime dose assures a better control of nocturnal
acid secretion than lansoprazole or esomeprazole.
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3.3.6. Administration Modes
Both IR capsules and DR omeprazole tablets should be ingested whole [32,33]. All the
remaining formulations can be prepared in a liquid form for administration. Apart from
water, applesauce was tested as a vehicle for DR capsule content [33]. The results were
dose-dependent: concomitant ingestion of applesauce and a DR 20 mg omeprazole capsule
decreased the mean Cmax value by 25% relative to consumption without applesauce;
however, no significant change was detected for 40 mg dose. Moreover, AUC of both
omeprazole doses remained unaffected; hence, co-administration of a DR omeprazole
capsule with applesauce can be safely recommended.
3.4. Pantoprazole
Pantoprazole (syn. pantoprazole sodium) is available in DR formulations: tablets and
granules to prepare an oral suspension, with the bioavailability of 77% [56].
3.4.1. Food Effect
Campos et al. [57] performed a randomized, open-label study in 98 healthy volunteers
to examine the effect of food on the pharmacokinetics of two pantoprazole enteric-coated
(EC) formulations. Each participant ingested a single 40 mg pantoprazole tablet while
fasting or with a high-fat breakfast that contained on average 800–1000 kcal. Although
the measured Cmax values were comparable under fasted and fed conditions, the presence
of food slightly decreased AUC0–∞ in both examined formulations (by 17% and 25%,
respectively) and significantly delayed tmax (by 4 and 5 h, respectively).
The results of the abovementioned studies and other similar studies [35,58] suggest
that concomitant intake of food may slow down pantoprazole absorption; however, the
clinical relevance of this effect is questionable [59]. Probably, for this reason, the recom-
mended administration of pantoprazole tablets with food may differ depending on the
country of registration. For example, according to the prescribing information of Protonix
(registered in the USA) and Proto-BYK (registered in Canada), both drugs can be taken with
or without food [56,59], while pantoprazole tablets available in Poland (e.g., Controloc, IPP)
are recommended to be taken 1 h before a meal [60].
Regarding granules for oral suspension formulation, the pharmacokinetic study re-
vealed that concomitant ingestion of 40 mg pantoprazole granules with a high-fat meal
may significantly delay tmax by 2 h and considerably reduce both AUC and Cmax (by 29%
and 51%, respectively) relative to the fasted conditions [56].
3.4.2. Dosing Regimen
We found only one study that investigated the influence of dosing regimen on the ef-
fectiveness of pantoprazole. In a randomized, double-blind trial [61], 12 healthy volunteers
were given 40 mg pantoprazole once a day for 1 week, before the morning or evening meal.
When administered in both schedules, pantoprazole effectively increased 24-h intragastric
pH relative to the baseline; however, higher 24-h median pH was observed for the morning
vs. evening regimen (3.3 vs. 2.7, baseline: 1.6). Interestingly, the differences in pH between
the schedules were greater for daytime period than for nighttime period. Müssig et al. [61]
concluded that pantoprazole should be preferably administered in the morning.
3.4.3. Administration Modes
While pantoprazole tablets need to be ingested whole, granules can be opened; this
provides a convenient alternative for children or patients with dysphagia [56]. In a random-
ized, open-label study of 25 healthy adults, Tammara et al. [62] compared two methods of
intake of 40 mg pantoprazole granules: with 5 mL (one teaspoon) of applesauce or with
5 mL of apple juice. Both administration methods resulted in comparable AUC and Cmax
values and hence can be considered bioequivalent.
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3.5. Rabeprazole
Rabeprazole (syn. rabeprazole sodium) is available in DR formulations: tablets and
capsules. The oral bioavailability is approximately 52% [63].
3.5.1. Food Effect
To assess the effect of a meal on the pharmacokinetic parameters of rabeprazole tablets,
Shinkai et al. [42] performed a randomized, open-label study in 12 healthy volunteers.
Each of the participants ingested a single 10 mg dose of rabeprazole either while fasting
or after breakfast that contained on average 712 kcal. No clinically relevant differences
were detected in AUC, Cmax, and t1⁄2 of rabeprazole between fasted and fed conditions.
However, in the presence of food, rabeprazole tmax was significantly delayed (by 2.5 h).
Similar changes were observed in several other studies [35,63,64], thus suggesting that
concomitant intake of rabeprazole with a meal may slow down the rate, but not the extend
of rabeprazole tablet absorption.
In two randomized, double-blind, placebo-controlled studies that included 69 healthy
subjects, Furuta et al. [23,24] investigated the influence of food on rabeprazole effectiveness
measured by changes in 24-h intragastric pH and percentage time at pH > 4. In the first
trial [23], the participants were administered a single 10 mg rabeprazole tablet (embedded
in a gelatin capsule due to the study design) either 15 min before or 30 min after the supper.
The supper contained 112.8 g of carbohydrates, 16.3 g of proteins, and 27.3 g of fat and had
on average 762 kcal. In the second trial [24], a rabeprazole tablet with the same dose and
formulation was ingested either 30 min before or 30 min after breakfast. In both studies,
no significant differences were observed in 24-h intragastric pH and percentage time at
pH > 4 for rabeprazole taken under fasted and fed conditions. Furuta et al. concluded that
the timing of administration with food does not influence rabeprazole tablet effectiveness.
In contrast, the effect of food on rabeprazole capsule formulation was found to be
considerable. In a randomized, open-label study of 53 healthy subjects, Thyssen et al. [65]
revealed that co-administration of a 10 mg DR rabeprazole capsule and a high-fat, high-
calorie meal may lead to a significant decrease in both AUC0–∞ and Cmax (by 27% and 55%,
respectively) and a significant delay in tmax as well (by 2 h).
3.5.2. Dosing Regimen
In a randomized, double-blind study of 20 patients with GERD, Pehlivanov et al. [66]
compared the effectiveness of morning and evening rabeprazole dosing. The participants
received 20 mg rabeprazole either (1) 30 min before breakfast or (2) 30 min before dinner.
At the beginning and after 7 days of study, total and nocturnal esophageal acid exposure
and the mean NAB duration were determined. Relative to the morning intake, the evening
schedule normalized total esophageal acid exposure in a higher number of patients (71.4%
vs. 42.8%). Moreover, the evening regimen provided better control of nocturnal gastroe-
sophageal reflux. Not only the mean NAB duration was significantly lower (3.4 ± 1.5 h vs.
4.1 ± 1.8 h), but also the number of supine reflux episodes in the 24 h period (6 vs. 28). On
the basis of these results, Pehlivanov et al. recommended taking rabeprazole before the
evening meal as the preferred dosing regimen for GERD patients, especially for those with
nocturnal symptoms.
In contrast, in a later study of 10 healthy subjects, Miki et al. [67] suggested that
post-breakfast and pre-dinner repeated intake of lower (10 mg) rabeprazole dose is equally
effective. For both dosing schedules, rabeprazole exhibited a comparable gastric acid
inhibitory effect measured as the percentage time of pH > 4 in a 24-h period (57.7% ± 7.5
vs. 57.0% ± 7.6, respectively).
3.5.3. Administration Modes
According to the prescribing information of registered rabeprazole formulations,
tablets need to be swallowed whole, while capsules should be opened and their content
(granules) sprinkled onto a small amount of soft food [63]. In a randomized, open-label
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study of 35 healthy adults, Thyssen et al. [68] compared the pharmacokinetic parameters of
10 mg rabeprazole granules when mixed with different vehicles: (1) a strawberry-flavored
suspension, (2) 15 mL of applesauce, (3) 15 mL of yogurt, (4) 5 mL of infant formula,
and (5) a water suspension. No significant differences were observed in pharmacokinetic
parameters between the tested administration modes; hence, Thyssen et al. concluded that
all the investigated vehicles are bioequivalent.
3.6. Lansoprazole
Lansoprazole is available in DR formulations: capsules, ODT, and granules for oral
suspension. The oral bioavailability is 80–85% [11].
3.6.1. Food Effect
In a randomized, open-label study in 12 healthy men, Bergstrand et al. [69] evaluated
the effect of a meal on lansoprazole pharmacokinetic parameters. The participants were
given a single 30 mg lansoprazole capsule under fasted conditions or with a standardized
breakfast. The meal consisted of two slices of white bread with butter, two slices of
cheese (40 g), 50 g of muesli, 200 g of yogurt, 300 mL of milk, and 150 mL of tea or coffee.
Concomitant intake of lansoprazole and breakfast resulted in a significant decrease in AUC
and Cmax (both by approximately 50%) and a significant delay of tmax (from 1.8 to 3.3 h).
Bergstrand et al. proposed several possible mechanisms explaining the interaction between
lansoprazole and food, such as (1) binding of drug molecules to food, (2) retarded gastric
emptying in the presence of food and hence delayed drug absorption, and (3) higher gastric
acidity after a meal and subsequently increased breakdown of enteric coating of the capsule.
Comparable results were obtained in other similar studies [70,71], which suggested that
lansoprazole capsules should not be co-administered with meals.
Fujiwara et al. [72] suggested that the food intake may also affect lansoprazole bioavail-
ability in ODT formulation. Nine healthy subjects were administered a single 30 mg OD
tablet either while fasting or 15 min after breakfast. Relative to fasted conditions, the pres-
ence of meal significantly decreased both AUC0–∞ and Cmax (by 32% and 50%, respectively)
and significantly delayed tmax (from 2 to 3.3 h).
In contrast to the abovementioned studies, Moules et al. [73] concluded that inhibition
of gastric acid by lansoprazole is not altered in the presence of food. In a randomized,
double-blind study, 13 healthy volunteers were given either a 30 mg lansoprazole capsule
or placebo (1) before breakfast or (2) after finishing breakfast. The 24-h intragastric pH
was measured before treatment and after 1 week. Median acid inhibition values and the
median time of pH > 3 were comparable under fasted and fed conditions (95.4% vs. 97.4%
of baseline value and 20.75 h vs. 22.07 h, respectively).
In another randomized, double-blind study in 16 healthy volunteers, Brummer et al. [74]
revealed that on the first day of treatment, the median 24-h intragastric pH significantly
differed for lansoprazole 30 mg capsule intake while fasting and with a meal (pH = 1.4
vs. 3). However, the food effect was not maintained after 15 days (pH = 4.1 vs. 4.3). The
authors suggested that the interaction between lansoprazole and food may be important
only at the beginning of therapy.
Hatlebakk et al. [43] assessed whether lansoprazole should be administered shortly
before a meal or without a meal. In a pharmacodynamic study of 21 healthy volunteers,
lansoprazole 20 mg capsule was taken either 15 min before breakfast or 4 h before lunch.
Breakfast contained the number of calories typical for each participant and included a piece
of bread or a muffin, milk or yogurt, and coffee or tea. After 8-h intragastric pH recording,
the median percentage time of pH < 4 differed for lansoprazole taken shortly before and
without food (14.2% vs. 48.1%, respectively). Hatlebakk et al. proposed the following
explanations of this result: (1) meal intake stimulates acid secretion, and low gastric pH is
essential for PPI activation, (2) after meal consumption, proton pumps are activated and
recruited to the surface of parietal cells, and PPIs can block only activated proton pumps.
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Hence, lansoprazole should be taken shortly before a meal and not without it to maintain
the optimal control of gastric juice acidity during the day.
3.6.2. Lansoprazole and Grapefruit Juice Consumption
Initially, in the small intestine and subsequently in the liver, lansoprazole is trans-
formed into two major metabolites: 5-hydroxylansoprazole and lansoprazole sulfone [75].
The hydroxylation process is catalyzed mainly by CYP2C19, while the sulfoxidation pro-
cess by CYP3A4 [76]. Grapefruit juice constituents have been shown to inhibit both these
enzymes in the intestine; hence, the potential risk of interaction between lansoprazole and
GFJ exists.
Uno et al. [76] performed a randomized study of 21 healthy subjects to assess the
effect of GFJ on the pharmacokinetics of lansoprazole and its metabolites. Thirty minutes
before the intake of a 60 mg lansoprazole capsule, the participants ingested either 200 mL of
water or 200 mL of freshly prepared GFJ. After GFJ consumption, no significant differences
were observed in the AUC of lansoprazole metabolites as well as in Cmax, tmax, or t1⁄2 of
lansoprazole and its metabolites. However, relative to the water group, the AUC of lanso-
prazole was slightly, but significantly, lowered (by 18%) in the GFJ group. Consequently,
the sulfoxidation index—the AUC ratio of lansoprazole sulfone to lansoprazole—was also
considerably decreased (by 42%) by GFJ ingestion. On the basis of these results, Uno
et al. concluded that GFJ may affect the formation of lansoprazole sulfone by inhibiting
CYP3A4. Nevertheless, the authors suggested that this effect, occurring only in the small
intestine, might not influence lansoprazole pharmacokinetics due to the relatively high
drug bioavailability.
In another randomized, double-blind, placebo-controlled study, Miura et al. [75] inves-
tigated the effect of GFJ on the metabolism of lansoprazole in 18 healthy volunteers of three
different CYP2C19 genotype groups: heterozygous extensive metabolizers, homozygous
extensive metabolizers, and poor metabolizers. Each of the participants ingested either
200 mL of water or 200 mL of fresh GFJ and subsequently took a single 60 mg dose of
lansoprazole capsule. After GFJ consumption, no significant changes were detected in
Cmax or t1⁄2 values of both lansoprazole and lansoprazole sulfone in all three CYP2C19
genotype groups.
3.6.3. Lansoprazole and Alcohol Consumption
To evaluate the risk of interaction between lansoprazole and ethanol, Battiston et al. [77]
measured the drug effect on the gastric and hepatic activity of the ethanol-metabolizing
enzyme—alcohol dehydrogenase. The influence of lansoprazole on ethanol metabolism
was found to be neutral; hence, the authors suggested that, in contrast to imidazole deriva-
tives (e.g., famotidine, ranitidine), therapy with lansoprazole may be continued in patients
who are unable to quit or reduce ethanol consumption.
3.6.4. Dosing Regimen
To compare the effect of morning and evening lansoprazole intake on 24-h intragastric
acidity, Fraser et al. [78] performed a randomized, double-blind, placebo-controlled study.
For 7 days, 32 healthy subjects were administered 30 mg lansoprazole dose either (1) in
the morning—30 min before breakfast or (2) in the evening—at least 2 h after a meal. The
morning intake resulted in a higher decrease of 24-h intragastric acidity relative to the
evening regimen (36% vs. 42% of placebo value, respectively). Interestingly, significant
changes were observed between morning and evening dosing only for a daytime interval.
During the night, both lansoprazole dosing regimens were equally effective in controlling
gastric acidity. Fraser et al. concluded that generally, morning dosing is favorable; how-
ever, an evening regimen can be beneficial for patients with mainly nocturnal symptoms.
Sanders et al. [79] obtained similar results in a former 7-day study and additionally ob-
served that morning dosing may improve 30 mg lansoprazole bioavailability relative to
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the evening regimen (AUC0–24 (ng·mL/h): 2517 ± 1737 vs. 1065 ± 684, Cmax (ng/mL):
1054 ± 379 vs. 381 ± 249).
In contrast to the abovementioned studies, Hongo et al. [80] suggested that morning
and evening lansoprazole administration is equally effective. In a small study of eight
healthy volunteers, a 30 mg lansoprazole capsule was given once a day for a week, either
(1) in the morning—3 h before a meal or (2) in the evening—3 h after a meal. Next, 24-h
intragastric pH and percentage time of pH > 4 were measured at the beginning of the study
and after 7 days. Both dosing regimens increased intragastric pH when compared with
the control group (regimen (1): pH = 4.3, control: pH = 1.6; regimen (2): pH = 4.6, control:
pH = 2.1). No significant differences were found in all measured values between morning
and evening lansoprazole intake. In a randomized study of 10 healthy subjects, Miki
et al. [67] confirmed these results for a lower—15 mg dose of lansoprazole. When taken
both after breakfast and before dinner, lansoprazole exhibited a comparable gastric acid
inhibitory effect measured as the percentage time of pH > 4 in a 24-h period (55.5% ± 10.8%
vs. 54.6% ± 10.7%, respectively).
3.6.5. Administration Modes
The standard approach to administer lansoprazole capsules is to swallow them whole.
However, this might be problematic in children and patients with dysphagia. Hence, Chun
et al. [81,82] investigated whether admixing lansoprazole capsule content with various
vehicles would be an appropriate administration mode. In two randomized, open-label
studies in 43 healthy volunteers, a single dose of 30 mg lansoprazole was given either
(1) as an intact capsule or emptied into (2) a tablespoon of yogurt, (3) a tablespoon of
strained pears, (4) Ensure pudding, (5) cottage cheese, (6) 180 mL of orange juice, or (7)
180 mL of tomato juice. For lansoprazole intake with cottage cheese, a considerably higher
tmax was observed relative to ingestion of an intact capsule (2.1 and 1.5 h, respectively).
Moreover, when capsule content was administered with orange juice, AUC0–∞ values
were lower (3429 vs. 3755 ng·mL/h), and tmax was significantly delayed (from 1.7 to
3 h) as compared to those for the intact capsule. However, all these changes were in an
acceptable equivalence range; moreover, no other statistically significant differences in
pharmacokinetic parameters were observed between the regimens. Chun et al. concluded
that all investigated vehicles can be used to administer lansoprazole capsules, without a
negative effect on drug bioavailability.
Regarding ODT formulation, Iwasaki et al. [83] examined the influence of intake with
water on lansoprazole absorption. Twelve healthy men were administered 30 mg ODT
lansoprazole with or without 150 mL of water. No significant changes in AUC0–24 and
Cmax were detected between both administration modes.
3.7. Dexlansoprazole
Dexlansoprazole is available in dual delayed-release (DDR) capsules and DR orally
disintegrating tablets. Each dual delayed-release capsule of dexlansoprazole contains two
different sets of enteric-coated granules that disintegrate at two different pH levels—in the
duodenum and the small intestine. This allows achieving two peaks of the drug concentra-
tions [84]. The pharmacokinetic studies of dexlansoprazole modified-release formulation
showed a plasma concentration–time profile, with two distinct peaks, occurring 1–2 h and
4–5 h after dosing and what should be noted 24-h intragastric pH-recordings confirm a pro-
longed acid inhibition [85]. Consequently, both the therapeutic level of dexlansoprazole in
blood and its gastric acid inhibitory effect are maintained longer relative to other PPIs [84].
Dexlansoprazole was found to be highly effective and superior to lansoprazole in healing
erosive esophagitis [86].
3.7.1. Food Effect
In a randomized, open-label, placebo-controlled study, Lee et al. [87] assessed the
influence of food on the pharmacokinetic and pharmacodynamic parameters of dexlanso-
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prazole. Forty-eight healthy volunteers were given a DDR 90 mg capsule (1) while fasting,
(2) 5 min before breakfast, (3) 30 min before breakfast, or (4) 30 min after breakfast. The
breakfast contained a high amount of fat and consisted of two slices of toast with butter,
two strips of bacon, two eggs fried in butter, 4 oz (114 g) of hash-brown potatoes, and 8 oz
(237 mL) of whole milk. The presence of food—ingested either before or after dexlansopra-
zole administration—increased both area under the curve (AUC) (by 9–21%) and Cmax (by
12–31%) as compared to that in fasted conditions. Additionally, for regimen (4), tmax was
delayed significantly (by 2 h). Lee et al. [87] also measured intragastric pH before and after
dexlansoprazole administration under fasted and fed conditions. Because no clinically
important differences were observed, the researchers concluded that DDR dexlansoprazole
capsules can be ingested regardless of food. In another study [88], the percentage time at
pH > 4 over a 24-h period was evaluated for dexlansoprazole taken while fasting and after
a meal; the measured values were 64% and 57%, respectively. However, because of only
a slight decrease, it was concluded that dexlansoprazole may be administered without
food intake.
The effect of food was also examined for orally disintegrating tablets (ODT) of dexlan-
soprazole. Kukulka et al. [89] performed a randomized, open-label study in 65 healthy
subjects who were administered a single 30 mg ODT of dexlansoprazole either while fasting
or 30 min after a high-fat breakfast. The breakfast contained 800 to 1000 kcal, 50% of which
was derived from fat. The presence of food significantly delayed tmax (from 4 to 6 h) and
decreased Cmax by approximately 38%; however, AUC remained unaffected relative to the
fasting state.
3.7.2. Dosing Regimen
In a randomized, open-label study, Lee et al. [90] examined whether different dosing
regimens may influence the pharmacokinetics and pharmacodynamics of dexlansoprazole.
Forty-eight healthy volunteers ingested 60 mg dexlansoprazole DDR capsule 30 min before:
(1) breakfast (811 kcal); (2) lunch (714 kcal); (3) dinner (658 kcal); or (4) an evening snack
(344 kcal). On the 5th day of each regimen, AUC0-t, Cmax, and tmax of dexlansoprazole
and the 24-h intragastric pH were measured. Apart from the delay of tmax (by 2–3 h)
when dexlansoprazole was taken in each regimen relative to breakfast, no other clinically
significant differences in pharmacokinetic parameters were detected. Similarly, 24-h in-
tragastric pH values were comparable for all schedules of intake; hence, Lee et al. [90]
concluded that dexlansoprazole DDR capsules are equally effective regardless of the time
of administration.
3.7.3. Administration Modes
Generally, DDR dexlansoprazole capsules should be swallowed whole; however, it is
also allowed to open them and sprinkle enteric-coated granules with 15 mL (1 tablespoon)
of applesauce [88]. According to product characteristics, ODT formulation should be
placed on the tongue and swallowed without or with water [91]. Nevertheless, Kukulka
et al. [89] revealed that ingestion of ODT dexlansoprazole with water may lower both AUC
(by 15%) and Cmax (by 26%); hence, this administration mode should not be considered as
a bioequivalent administration option.
3.8. Limitations of Studies
We recognized several limitations of the presented studies, similar to our previous
investigation in this area [92,93] listed below:
• presence of the older studies—from the 1980s and 1990s,
• unavailable data—in some studies, PPI formulation was not mentioned, as well as the
quantitative and/or qualitative meal composition, not every drug formulation was
tested in the presence of food,
• the attendance of healthy volunteers in many of studies—such studies cannot be fully
translated to the clinical practice,
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• scarce data of PPI clinical effectiveness in the presence of food—the vast majority of
studies focused on changes in pharmacokinetic parameters (e.g., AUC, Cmax, tmax)
instead of more clinically relevant endpoints, such as response to treatment, symp-
toms alleviation or the lesion healing, limited data of PPI clinical effectiveness in
different dosing regimens—only single studies evaluated the effect of PPI dosing
regimen on nighttime syndromes, whereas the majority examined the changes in
pharmacodynamic parameters (e.g., 24 h intragastric pH) that cannot fully reflect the
clinical practice.
Overall, it is clear that there are gaps in the knowledge on interaction with medicines
for gastrointestinal diseases, especially with respect to the consequences of drug–food
interactions not only in influence of clinical significance but also cost and overall impact on
the population which was suggested previously [94,95].
Table 1 presents the summary of the most important information about the effect of
food on the pharmacokinetics and pharmacodynamics of PPIs as well as recommendations
for appropriate dosing regimen and intake concerning meals. We are convinced that
knowledge on this subject is vital to professionally educate patients with the aim to
improve their compliance and increase the effectiveness of PPI therapy.
Table 1. Summary of recommendations for appropriate intake of different formulations of proton pump inhibitors with
food and the time of the day.
Drug Formulation Food Effect Recommended Intake Regarding Food Recommended Dosing Regimen
Esomeprazole
DR capsules
after single dose: ↓ AUC
(by 43–53%), ↓ Cmax
(74–78%) [17,19–21],
↑ tmax (by 2.4–3 h) [16]
after repeated doses: ↓
AUC (by 25%), ↓ Cmax (by
23%) [17]
- should be taken 60 min before a meal [25]
- should be swallowed whole or with
content mixed with 15 mL of
applesauce [19,31] - can be administered both in
the morning or in the
evening [27]
- dosing regimen should be
individually chosen based on
the patient’s syndrome
pattern [27]
DR granules for oral
suspension no studies found
- should be taken 60 min before a meal [25]
- granules should be mixed with 5–15 mL
of water [25]
DR tablets no studies found
- can be taken with or without food [29]
- should be swallowed whole or dispersed
in a water [29]
Omeprazole
IR capsules
↓ AUC (by 24 and 28%,
depending on the study), ↓
Cmax (by 47 and 63%,
depending on the
study) [32,34,35], ↑ tmax (by
0.6 h) [34,35]
- should be taken 60 min before a meal [32]
- should be swallowed whole with
water [32]
- generally, should be taken in
the morning [51,52]
- evening intake can be
beneficial for patients with
nocturnal acid breakthrough
or nocturnal reflux [54]
IR powder for oral
suspension
↓ AUC (by 24%), ↓ Cmax (by
63%) [32]
- should be taken 60 min before a meal [32]
- packet content should be emptied into 30
mL of water [32]
DR orally
disintegrating tablets
↓ AUC (by 19%), ↓ Cmax (by
56%), ↑ tmax (by 2 h) [40]
- should be taken 60 min before a meal [40]
- should be placed on the tongue to
disintegrate and swallowed, with or
without water [40]
DR capsules
↓ AUC (by 35–38%) [34], ↓
Cmax (by 24–40% and
58–63%, depending on the
study) [36,38],
↑ tmax (by 2 h) [36]
- should be taken 60 min before a meal [33]
- should be swallowed whole or with
content mixed with 15 mL of
applesauce [33]
DR granules for oral
suspension no studies found
- should be taken 60 min before a meal [33]
- should be mixed with 5–15 mL of
water [33]
DR tablets
no significant changes in
AUC and Cmax, ↑ tmax (by
1.3 h) [41]
- can be taken with or without food [41]
- should be swallowed whole with
water [41]
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Table 1. Cont.
Drug Formulation Food Effect Recommended Intake Regarding Food Recommended Dosing Regimen
Pantoprazole
DR tablets
slightly ↓ AUC (by
17–25%), no significant
changes in Cmax, ↑ tmax (by
4–5 h) [57]
- can be taken with or without food [56,59]
- should be swallowed whole with
water [56,59]
- preferably should be
administered in the
morning [61]
DR granules for oral
suspension
↓ AUC (by 29%), ↓ Cmax (by
51%), ↑ tmax (by 2 h) [56]
- should be taken 30 min before a meal [56]
- content should be sprinkled into 5 mL of
applesauce/apple juice [56,62]
- do not mix with water or other liquids or
food [56]
Rabeprazole
DR capsules ↓ AUC (by 27%), ↓ Cmax (by55%), ↑ tmax (by 2 h) [65]
- should be taken 30 min before a meal [63]





- can be administered both in
the morning or in the
evening [67]
- evening intake can be
beneficial for patients with
nocturnal acid breakthrough
or nocturnal reflux [66]
DR tablets
no significant changes in
AUC and Cmax, ↑ tmax (by
2.5 h) [42]
no significant changes in
median intragastric
pH [23,24]
- can be taken with or without food [63]




↓ AUC and ↓ Cmax (both by
50%), ↑ tmax (by 1.5 h) [69]
median intragastric pH not
altered [73,74]
- should be taken 30 min before a meal
[69,71]
- should be swallowed whole or with
content mixed with 15 mL of
applesauce/yoghurt/strained
pears/Ensure pudding/cottage
cheese/60 mL of apple juice/orange
juice/tomato juice [81,82]
- can be administered both in
the morning or in the evening





↓ AUC (by 32%), ↓ Cmax (by
50%), ↑ tmax (by 1.3 h) [72]
- should be taken 30 min before a
meal [71,72]
- should be placed on the tongue to
disintegrate and swallowed, with or
without water [71]
Dexlansoprazole DDR capsules not significant [87]
- can be taken with or without food [87,88]
- should be swallowed whole or with
content sprinkled onto 15 mL of
applesauce or water [88]
- can be administered
irrespective of the time of the
day; however, preferably at
the same time every day [90]
DR orally
disintegrating tablets
no significant changes in
AUC, ↓ Cmax (by 38%), ↑
tmax (by 2 h) [89]
- should be taken 30 min before a meal [91]
- should be placed on the tongue to
disintegrate and swallowed, preferably
without water [89]
DR—delayed-release formulation; DDR—dual-delayed-release formulation; IR—immediate-release.
4. Summary
The studies discussed above indicate that concomitant intake of PPIs with a meal may
affect both their bioavailability and effectiveness; however, the influence of food strongly
depends on the type of drug and formulation. Generally, esomeprazole, lansoprazole, and
omeprazole are more vulnerable to interactions with food than dexlansoprazole, pantopra-
zole, and rabeprazole. DDR capsules of dexlansoprazole are the most food resistant of the
available PPI formulations; hence, they can be administered with or without meals and
should be the first choice for patients with poor compliance. According to the results of pre-
sented studies or product characteristics, DR tablets of all PPIs can be taken irrespectively
of food as well. Nevertheless, the real importance of that recommendation is questionable,
unless the possible reason for higher food resistance of DR tablets formulation will be
established. What should be noted, the choice of the proper schedule of PPI administration
should be based on the patient’s symptoms and individual dosing preferences.
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We found evidence that PPIs (lansoprazole and omeprazole) do not interact with
ethanol; thus, therapy with these drugs should not be discontinued in patients who are
unable to quit or reduce alcohol consumption.
We identified several studies that investigated the effect of GFJ on lansoprazole or
omeprazole bioavailability; however, the clinical relevance of this interaction remains
unclear. Therefore, regular but not occasional GFJ consumption during therapy with PPIs
should be avoided. A similar recommendation can be made for cranberry juice intake.
Except for pantoprazole, PPIs can be administered both in the morning or in the
evening; however, morning intake generally provides better daytime control of gastric
acidity. In most cases, the choice of the proper schedule of administration should be based
on the patient’s symptoms and individual dosing preferences.
New formulations of PPIs, or novel long-duration PPIs such as ilaprazole, AGN
201904-Z, azeloprazole or anaprazole, have been developed recently, with a better effect on
nocturnal acidity and faster symptom relief. Although they have not been introduced into
the therapy yet, they may represent an opportunity for more effective treatment [96].
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